Principal Investigator
Richard Preston
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20210474
Clinical Trial Summary
AN OPEN-LABEL, SINGLE AND MULTIPLE-DOSE TRIAL TO ASSESS THE EFFECTS OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF LANIFIBRANOR
Phase
Phase I
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Alisa Danielyan
Phone Number
+1 (305) 2435930
Email
axd2423@miami.edu